Market
Primary competitor to Zepbound in sleep apnea treatment by 2025?
2
Resolution / Starting Odds
Novo Nordisk's Wegovy • 25%
Pfizer's Danuglipron • 25%
AstraZeneca's Roxadustat • 25%
Other • 25%
Pharmaceutical industry reports and sales data
Story
FDA Approves Eli Lilly's Weight-Loss Drug Zepbound as First Treatment for Obstructive Sleep Apnea
Dec 20, 2024, 10:17 PM
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's weight-loss drug Zepbound (tirzepatide) as the first and only prescription medication for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. This approval allows the drug to be used in combination with a reduced-calorie diet and increased physical activity. Clinical studies have shown that patients treated with Zepbound experienced a mean reduction of 63% in the apnea-hypopnea index (AHI), equating to about 30 fewer breathing interruptions per hour, and up to 50% of patients had no symptoms after one year. The approval opens the door for broader insurance coverage of the medication, marking a significant advancement in the management of obstructive sleep apnea, a condition affecting approximately 39 million adults in the United States.
View original story
Similar markets
10% to 20% • 25%
Less than 10% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
0 • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
More than 30% • 25%
10% to 20% • 25%
20% to 30% • 25%
Zepbound • 25%
CPAP Machines • 25%
Other Pharmaceuticals • 25%
Surgical Treatments • 25%
Zepbound • 25%
CPAP devices • 25%
Alternative medications • 25%
Other treatments • 25%
200,001 to 300,000 • 25%
Less than 100,000 • 25%
100,000 to 200,000 • 25%
More than 300,000 • 25%
Less than 60% • 25%
60% to 70% • 25%
70% to 80% • 25%
More than 80% • 25%